Aptamers: A promising chemical antibody for cancer therapy
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
// Gang Zhou 1 , George Wilson 1 , Lionel Hebbard 2 , Wei Duan 3 , Christopher Liddle 1 , Jacob George 1 and Liang Qiao 1 1 Storr Liver Centre, Westmead Millennium Institute for Medical Research, University of Sydney and Westmead Hospital, Westmead, NSW, Australia 2 Discipline of Molecular and Cell Biology, James Cook University, Townsville, QLD, Australia 3 School of Medicine, Deakin University, Waurn Ponds, VIC, Australia Correspondence to: Liang Qiao, email: // Wei Duan, email: // Keywords : aptamers, SELEX, siRNA, cancers, target therapy Received : October 25, 2015 Accepted : January 24, 2016 Published : February 03, 2016 Abstract Aptamers, also known as chemical antibodies, are single-stranded nucleic acid oligonucleotides which bind to their targets with high specificity and affinity. They are typically selected by repetitive in vitro process termed systematic evolution of ligands by exponential enrichment (SELEX). Owing to their excellent properties compared to conventional antibodies, notably their smaller physical size and lower immunogenicity and toxicity, aptamers have recently emerged as a new class of agents to deliver therapeutic drugs to cancer cells by targeting specific cancer-associated hallmarks. Aptamers can also be structurally modified to make them more flexible in order to conjugate other agents such as nano-materials and therapeutic RNA agents, thus extending their applications for cancer therapy. This review presents the current knowledge on the practical applications of aptamers in the treatment of a variety of cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · cited 2×
“CL-42 (RNA) IL4Rα Blocks IL4Rα-STAT6 signaling Inhibits in vivo tumor growth of mammary carcinoma [78]”
BackgroundThe extracellular matrix: A dynamic niche in cancer progression
Lu, P., Weaver, V. M., & Werb, Z. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201102147 · Cited by 3,024 · cited 1×
“It is demonstrated that disorganization or remodeling of ECM is proposed to promote cellular transformation and/ or provide supportive tumorigenic microenvironment for cancer stem cells [37].”
BackgroundDiscovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer
Bates, P. J., Laber, D. A., Miller, D. M., Thomas, S. D., & Trent, J. O. (2009) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2009.01.004 · Cited by 874
Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth
Mahlknecht, G., Maron, R., Mancini, M., Schechter, B., Sela, M., & Yarden, Y. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1302594110 · Cited by 169 · cited 2×
“In addition, the trimeric aptamer against HER2 was found to be capable of engendering 2-fold stronger tumor inhibitory effects than that of HER2 antibodies in patients with gastric cancer [35, 36].”
BackgroundGupta, S., Hirota, M., Waugh, S. M., Murakami, I., Suzuki, T., Muraguchi, M., Shibamori, M., Ishikawa, Y., Jarvis, T. C., Carter, J. D., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.532580 · Cited by 151 · cited 1×
“These aptamers are as effective as their respective antibodies in blocking the function of cognate targets and promoting protective immunity, representing a novel therapeutic alternative for cancer treatment [80-83].”
Background
Cited by
Komiyama, M., Yoshimoto, K., Sisido, M., & Ariga, K. (2017) · Bulletin of the Chemical Society of Japan · doi:10.1246/bcsj.20170156 · Cited by 296
Selection of Nucleic Acid Aptamers Targeting Tumor Cell-Surface Protein Biomarkers
Mercier, M.-C., Dontenwill, M., & Choulier, L. (2017) · Cancers · doi:10.3390/cancers9060069 · Cited by 113
“Analogous to antibodies in their range of target recognition and variety of applications, they are referred as ‘chemical antibodies’ [15].”
BackgroundYang, Y., Qiao, L., Jiang, Y., Wang, Z., Zhang, D., Buratto, D., Huang, L., & Zhou, R. (2026) · eLife · doi:10.7554/elife.107785 · Cited by 2
Self-citationYang, Y., Qiao, L., Jiang, Y., Wang, Z., Zhang, D., Buratto, D., Huang, L., & Zhou, R. (2026) · eLife · doi:10.7554/elife.107785.4 · Cited by 1
Self-citation
Metadata
- Authors
- Zhou, G., Wilson, G., Hebbard, L., Duan, W., Liddle, C., George, J., & Qiao, L.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-02-03
- Volume
- 7
- Issue
- 12
- Pages
- 13446-13463
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2306330132
- Cited by
- 134
- References
- 5
- FWCI
- 5.87
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.